If you typed Accelagen into a search box, you are probably building a CRO shortlist. This article uses only what Accelagen publishes (accelagen.com.au) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What Accelagen publishes
Accelagen is a Melbourne regulatory and clinical firm founded in 2010 that can act as local sponsor. It markets to first-time and seed-stage sponsors of devices and small molecules. It publishes a case of ethics approval in 42 days for a US medical device company after two earlier rejections (sponsor not named), and first-in-human cases including Memo Therapeutics' anti-BKV therapy.
Accelagen vs bioaccess®
| Dimension | Accelagen | bioaccess® |
|---|---|---|
| Core focus | Australian RA + CRO + local sponsor | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If this is your first Australian trial and you want regulatory, local sponsor and CRO in one boutique, Accelagen fits.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Accelagen, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not Accelagen features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the Accelagen public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply